Lloyd A Rowland insider trades

Open-market stock purchases and sales by Lloyd A Rowland, General Counsel at CytomX Therapeutics, Inc, from SEC Form 4 filings since Feb 2, 2010.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -71%.

Recent trades

No open-market trades in the last 12 months.

Companies traded

  • CTMX CytomX Therapeutics, Inc: 1 buy, 7 sales, last Mar 18, 2025
  • XNCR Xencor Inc: other filings, last Jan 26, 2016
  • AMLN Amylin Pharmaceuticals Inc: 2 sales, last Aug 8, 2012

Get free alerts when Lloyd A Rowland files a new trade →